Category - Developments

Developments

IntelGenx receives Canadian patent notice for Loxapine VersaFilm

The Canadian Intellectual Property Office (“CIPO”) has issued a notice of allowance for IntelGenx’s (TSXV:IGX; OTCQX:IGXT) first Canadian patent application for its VersaFilm technology. Entitled, “Loxapine Film Oral...

July 5, 2018

Developments

ASLAN Pharma applies for first-in-man study of ASLAN004

ASLAN Pharmaceuticals (TPEx:6497; NASDAQ:ASLN) has applied to the Singapore Health Sciences Authority to conduct a Phase 1 clinical trial of ASLAN004. The single ascending dose study will recruit healthy volunteers and...

July 3, 2018

Developments

Urotronic Optilumedrug-coated balloon catheter licensed in Canada

Closely-held Urotronic of Plymouth, MN has received a license to begin treating urethral strictures with its Optilume drug-coated balloon (DCB) catheter in Canada. “We are quite excited to see this come to market,” Dr...

June 28, 2018

Developments

Aquinox Pharma AQX-1125 fails Phase 3 trial

Aquinox Pharmaceuticals (NASDAQ:AQXP) announced that the Phase 3 LEADERSHIP 301 clinical trial, evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome, failed to...

June 27, 2018

Developments

IntelGenx receives notice of European patent grant for Rizaport VersaFilm

IntelGenx (TSXV:IGX; OTCQX:IGXT) said the European Patent Office (EPO) has issued a notice of intention to grant the first key patent allowed in Europe for the company’s VersaFilm technology. The patent is entitled...

June 19, 2018

Developments

Ortho RTi posts positive rotator cuff repair data

Ortho Regenerative Technologies (CSE:ORTH) reported positive outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from Montreal’s École...

June 13, 2018

Developments

IntelGenx Montelukast VersaFilm featured in peer-reviewed journal

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a peer-reviewed paper entitled, “2018 Alzheimer’s Disease Facts and Figures,” published in the March 2018 issue of Alzheimer’s & Dementia: The Journal of the...

June 6, 2018

Developments

Titan Pharma, Braeburn terminate Probuphine license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn agreed to terminate a December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Under the...

May 30, 2018

Developments

Ortho RTi receives European patent allowance

Ortho Regenerative Technologies (CSE:ORTH) received a notice of allowance from the European Patent Office for a patent entitled, “Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma...

May 23, 2018

Developments

Cara Therapeutics licenses KORSAUVA to Vifor Fresenius JV

Cara Therapeutics (NASDAQ:CARA) licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in...

May 23, 2018

Category - Developments

Subscribe